Revocation of the conditional marketing authorisation of a cancer medicine: The olaratumab experience

Eur J Cancer. 2019 Dec:123:25-27. doi: 10.1016/j.ejca.2019.09.020. Epub 2019 Oct 23.

¹ European Medicines Agency, the Netherlands. Electronic address: [email protected].
² European Medicines Agency, the Netherlands; Agencia Espanola de Medicamentos y Productos Sanitarios, Spain. Electronic address: [email protected].
³ European Medicines Agency, the Netherlands; University of Rome "La Sapienza", Italy. Electronic address: [email protected].
⁴ European Medicines Agency, the Netherlands. Electronic address: [email protected].
⁵ European Medicines Agency, the Netherlands; Bundesinstitut für Arzneimittel und Medizinprodukte, Germany. Electronic address: [email protected].
⁶ European Medicines Agency, the Netherlands. Electronic address: [email protected].

No abstract available

Keywords: Clinical trials; Drug development; Marketing authorisation; Regulation; Sarcoma.

Publication types